CareFirst files second amended US complaint against Johnson & Johnson in case over Stelara
MLex Summary: CareFirst filed its second amended US antitrust complaint accusing Johnson & Johnson of unlawfully delaying the introduction of biosimilar competition for Stelara, a treatment for autoimmune diseases. According to the...To view the full article, register now.
Already a subscriber? Click here to view full article